首页> 美国卫生研究院文献>Open Forum Infectious Diseases >Decreasing Vancomycin Utilization in the NICU by Optimizing Treatment Decisions in Suspected Late Onset Sepsis
【2h】

Decreasing Vancomycin Utilization in the NICU by Optimizing Treatment Decisions in Suspected Late Onset Sepsis

机译:通过优化可疑迟发性败血症的治疗决策来减少重症监护病房中万古霉素的利用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundLate Onset Sepsis (LOS) is frequently suspected in NICU patients in the setting of nonspecific clinical symptoms. Based on institutional antibiogram data, empiric treatment of LOS in our NICU is vancomycin and amikacin with a plan to deescalate or discontinue based on culture results and symptomatology. Baseline data in our NICU revealed vancomycin overuse where vancomycin was continued past 48 hours of culture negativity, after Gram-negative urinary tract infection (UTI) was diagnosed, or for urine cultures reported with multiple organisms or < 10,000 CFU/mL. Our objective was to eliminate inappropriately prolonged empiric use of vancomycin for suspected LOS or UTI.
机译:在非特异性临床症状的背景下,NICU患者经常怀疑背景迟发性败血症(LOS)。根据机构抗菌素数据,在我们的重症监护病房中,LOS的典型治疗是万古霉素和丁胺卡那霉素,并计划根据培养结果和症状进行降级或停药。我们的重症监护病房(NICU)的基线数据显示万古霉素过度使用,其中万古霉素在诊断出革兰氏阴性尿路感染(UTI)后或报告有多种生物体或<10,000 CFU / mL的尿液培养后持续培养阴性超过48小时。我们的目标是消除万古霉素对可疑的LOS或UTI的不适当的长期经验性使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号